Cohort of STEMI Patients

CoHort of STEMI Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02822638

Acronym

STEMI

Enrollment

1204

Registered

2016-07-04

Start date

2009-08-31

Completion date

2016-05-31

Last updated

2016-07-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial Infarction

Keywords

Myocardial infarction, biomarkers, STEMI

Brief summary

Ischemic heart disease is the leading cause of mortality in industrialized countries. ST elevated acute myocardial infarction is one of its most frequent and deadly manifestation. In the last 20 years, STEMI mortality has been reduced by 50% with the advent of timely reperfusion (primary percutaneous intervention) and significant progression in pharmacologic intervention. However, death and heart failure incidence after STEMI remain elevated: up to 20% at one year. Also, therapeutic management following international guidelines is standardized toward a one-size fits all therapeutic management. In order to continue improving myocardial infarction outcomes, there is a need to better understand and individualize therapeutic targets such myocardial reperfusion injury, post reperfusion inflammation, adverse left ventricular (LV) remodeling …. This knowledge will allow us to propose new therapeutic strategies and in the long run strive towards personalized medicine. The aim objective of this cohort of STEMI patients is to identify new biological markers of injury and prognosis.

Interventions

OTHERSTEMI PATIENT Cohort

PCI

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age\> 18 years * Diagnosis of STEMI defined by ST segment elevation ≥ 0.2 mV in 2 contiguous leads on a 12-lead ECG. * Primary PCI within 12 hours of symptoms onset.

Exclusion criteria

* Diagnosis of STEMI not confirmed by angiography * Refusal to participate in the study or to sign the consent * Inability to give information to the subject about the study * Lack of medical social coverage * Deprivation of civil rights

Design outcomes

Primary

Measure	Time frame	Description
Change in Troponin	Day 0	Dosage of Troponin at hospital admission and 4 hours after Percutaneous coronary intervention (PCI)
Change in Creatine Kinase	Day 0	Dosage of Creatine Kinase at hospital admission and 4 hours after PCI

Secondary

Measure	Time frame	Description
New York Heart Association (NYHA) Class	at admission (Day 0)	—
Left ventricular ejection fraction (LVEF)	24 hours after PCI (Day 1)	LVEF measured by echocardiography

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026